DaVita (NYSE:DVA) Releases FY24 Earnings Guidance

DaVita (NYSE:DVA) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $9.25-10.05 for the period, compared to the consensus estimate of $9.63.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. StockNews.com downgraded DaVita from a strong-buy rating to a buy rating in a report on Saturday, June 8th. Truist Financial increased their target price on DaVita from $135.00 to $150.00 and gave the company a hold rating in a research report on Wednesday, May 15th. TD Cowen increased their target price on DaVita from $139.00 to $150.00 and gave the company a hold rating in a research report on Wednesday, July 24th. Finally, Barclays raised their price objective on DaVita from $133.00 to $150.00 and gave the stock an equal weight rating in a research report on Monday, May 6th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $146.00.

DaVita Stock Up 1.2 %

Shares of DaVita stock traded up $1.58 during trading hours on Tuesday, reaching $136.99. 1,266,370 shares of the company were exchanged, compared to its average volume of 835,260. DaVita has a 1 year low of $71.51 and a 1 year high of $147.93. The stock’s fifty day moving average is $140.65 and its 200 day moving average is $132.80. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. The firm has a market cap of $12.01 billion, a PE ratio of 15.39, a PEG ratio of 1.07 and a beta of 0.87.

Insider Buying and Selling at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $138.81, for a total transaction of $698,214.30. Following the completion of the sale, the director now owns 10,954 shares in the company, valued at $1,520,524.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.00% of the stock is currently owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.